1.85
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
Inhibikase Therapeutics Inc. Stock Analysis and ForecastUnrivaled growth potential - Autocar Professional
Is Inhibikase Therapeutics Inc. a good long term investmentPhenomenal investment performance - Autocar Professional
What analysts say about Inhibikase Therapeutics Inc. stockBreakout profit opportunities - Autocar Professional
What analysts say about Tianci International Inc. stockTriple-digit profit margins - jammulinksnews.com
How Inhibikase Therapeutics Inc. stock performs during market volatilityMarket Beating Strategy - Newser
What drives Inhibikase Therapeutics Inc. stock priceTremendous growth opportunities - jammulinksnews.com
What makes Inhibikase Therapeutics Inc. stock price move sharplyVolume Spike Monitors - Newser
What risks could impact Inhibikase Therapeutics Inc. stock performance2x Return Forecast - Newser
Why Inhibikase Therapeutics Inc. stock attracts strong analyst attentionSmart High Yield Swing Trades - beatles.ru
Inhibikase Therapeutics Approves Key Proposals at Annual Meeting - The Globe and Mail
Inhibikase Therapeutics shareholders elect directors and approve equity plan changes - Investing.com India
Inhibikase Therapeutics Soars 6.79% on Russell 2000 Index Addition - AInvest
Inhibikase Therapeutics, Inc.(NasdaqCM: IKT) added to Russell 2500 Index - MarketScreener
IKT SEC FilingsInhibikase Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Ludwig Enterprises appoints Garth Lees-Rolfe as independent director By Investing.com - Investing.com UK
Squarepoint Ops LLC Acquires Shares of 28,411 Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Millennium Management LLC Invests $462,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Northern Trust Corp Invests $208,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Inhibikase Therapeutics Insider Buyers Pleased With US$788k Return On Investment - simplywall.st
Inhibikase Therapeutics Reports Q1 2025 Financial Results - TipRanks
13,129 Shares in Inhibikase Therapeutics, Inc. (NYSE:IKT) Purchased by Stifel Financial Corp - Defense World
Inhibikase Therapeutics: Strategic Realignment and Financial Strength Justify Buy Rating - TipRanks
Inhibikase Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Inhibikase Therapeutics, Inc. SEC 10-Q Report - TradingView
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity - The Manila Times
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):